for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oxford Biodynamics PLC

OBD.L

現在値

42.00GBp

変化

0.50(+1.20%)

出来高

33,481

本日のレンジ

40.00

 - 

42.00

52週レンジ

40.00

 - 

125.00

∙ 約20分前の相場を表示しています。

価格

前日終値
41.50
始値
41.00
出来高
33,481
3か月平均出来高
2.36
高値
42.00
安値
40.00
52週高値
125.00
52週安値
40.00
発行済株式数
100.35
時価総額
42.15
予想PER
--
配当利回り
--

次のエベント

Full Year 2021 Oxford Biodynamics PLC Earnings Release

適時開示

その他

Oxford Biodynamics H1 Revenue 250,000 Stg Versus 190,000 Stg Year Ago

Oxford Biodynamics Signs Agreement With Agilent Technologies

Oxford Biodynamics FY Operating Loss Of 5 Mln Stg Vs. 3.7 Mln Stg Loss Year Ago

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oxford Biodynamics PLCとは

Oxford BioDynamics plc is a United Kingdom-based biotechnology company. The Company is engaged in advancing personalized healthcare by developing and commercializing medicine tests for life-changing diseases. It has developed a three dimensional (3D) genomic biomarker platform, EpiSwitch, which builds molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a range of indications. The platform discovers, evaluates, validates and monitors of biomarkers known as chromosome conformation signatures (CCSs). CCSs provides a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities. EpiSwitch supports precision medicine initiatives, including prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring.

業種

Biotechnology & Drugs

連絡先

26 Beaumont Street

OX1 2NP

United Kingdom

+44.1865.518910

http://www.oxfordbiodynamics.com/

エグゼクティブリーダーシップ

Matthew Wakefield

Non-Executive Independent Chairman of the Board

Jon Anthony Joseph Burrows

Chief Executive Officer, Executive Director

Paul Stockdale

Chief Financial Officer, Executive Director

Alexandre Akoulitchev

Chief Scientific Officer, Executive Director

Stephen Diggle

Non-Executive Director

統計

株価売上高倍率(過去12カ月)
--
株価売上高倍率(過去12カ月)
81.37
株価純資産倍率(四半期)
3.69
株価キャッシュフロー倍率
--
総負債/総資本(四半期)
4.54
長期負債/資本(四半期)
3.30
投資利益率(過去12カ月)
-39.37
自己資本利益率(過去12カ月)
-35.99

最新ニュース

最新ニュース

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up